J. Goldman & Co LP acquired a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 141,748 shares of the company's stock, valued at approximately $748,000. J. Goldman & Co LP owned about 0.69% of Protara Therapeutics at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of TARA. HBK Investments L P acquired a new position in Protara Therapeutics during the fourth quarter worth $106,000. Dimensional Fund Advisors LP bought a new stake in Protara Therapeutics in the 4th quarter valued at about $111,000. Bailard Inc. purchased a new stake in shares of Protara Therapeutics during the 4th quarter valued at approximately $157,000. Commonwealth Equity Services LLC raised its holdings in Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after acquiring an additional 17,572 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Protara Therapeutics by 21.0% during the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company's stock valued at $311,000 after acquiring an additional 29,514 shares during the period. Institutional investors and hedge funds own 38.13% of the company's stock.
Insider Activity
In other news, insider Jacqueline Zummo sold 21,224 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the sale, the insider now owns 98,861 shares of the company's stock, valued at $447,840.33. This represents a 17.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 12.50% of the company's stock.
Analysts Set New Price Targets
TARA has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Monday, April 28th. Scotiabank started coverage on shares of Protara Therapeutics in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price target on the stock. Lifesci Capital initiated coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They issued an "overweight" rating on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $20.40.
Read Our Latest Stock Analysis on TARA
Protara Therapeutics Stock Performance
Shares of TARA traded down $0.02 during mid-day trading on Thursday, reaching $3.11. The company had a trading volume of 297,534 shares, compared to its average volume of 776,535. The company has a market capitalization of $119.99 million, a price-to-earnings ratio of -1.10 and a beta of 1.73. The firm has a 50-day moving average price of $3.96 and a 200 day moving average price of $4.11. Protara Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $10.48.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.18. As a group, research analysts forecast that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.
Protara Therapeutics Profile
(
Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
See Also
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
